5 completed. 3 Phase 1, 2 Phase 2.
By phase and status
Follow setrobuvir: new trials by email Literature Review of setrobuvir trials Research Report on setrobuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls
danoprevir, ritonavir, setrobuvir - Healthy Volunteer | Phase 1 | Completed | 18 | 2012-11-01 | 2016-11-02 |
A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers
setrobuvir - Healthy Volunteer | Phase 1 | Completed | 40 | 2012-06-01 | 2016-11-02 |
A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C
peginterferon alfa-2a [Pegasys], placebo, ribavirin [Copegus] - Hepatitis C, Chronic | Phase 2 | Completed | 283 | 2011-01-01 | 2016-11-02 |
Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
placebo, ANA598, Peginterferon - HCV Infection | Phase 2 | Completed | 97 | 2009-09-01 | 2017-03-31 |
Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection
ANA598 200 mg bid or placebo, ANA598 400 mg bid or placebo, ANA598 800 mg bid or placebo - Chronic Hepatitis C | Phase 1 | Completed | 35 | 2008-10-01 | 2012-11-14 |
Conditions studied
Hepatitis C, Chronic (2) · Hepatitis C (1)
Sponsors
Hoffmann-La Roche (5)
Countries
Puerto Rico (2) · United States (2) · Hungary (1) · Netherlands (1) · Poland (1)
Results publications
PMID 25456558